CreatorsPublishersAdvertisers
View more in
Cancer

Dr. Shah on the Clinical Implications of Ide-Cel in Relapsed/Refractory Myeloma

onclive.com
 2021-09-10

Nina Shah, MD, discusses the clinical implications of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. Nina Shah, MD, a hematologist and oncologist, and an associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the clinical implications of idecabtagene vicleucel (ide-cel; Abecma) in patients with relapsed/refractory multiple myeloma.

www.onclive.com

Comments / 0

Comments / 0